05 Jun 2023 ANeuroTech receives IND approval from the FDA for pivotal Phase IIIB trial of adjunctive anti-depression drug, ANT-01 Member news
02 Jun 2023 Biotalys continues to demonstrate strength of first biocontrol in latest global field trials Member news
26 May 2023 Oxurion reaches enrollment target in KALAHARI Phase 2, Part B trial of novel PKal inhibitor THR-149 in diabetic macular edema Member news
24 May 2023 Galapagos announces start of Phase 2 study with selective TYK2 inhibitor, GLPG3667, in patients with dermatomyositis Member news
02 May 2023 Sequana Medical announces FDA clearance of IND application for DSR® 2.0 for treatment of congestive heart failure Member news
27 Apr 2023 Galapagos initiates Phase 3 program with filgotinib in patients with active axial spondyloarthritis Member news
26 Apr 2023 VIB and Ghent University develop new mRNA vaccines against bacterial infections Member news
20 Mar 2023 Bimekizumab Phase 3 data in hidradenitis suppurativa show clinically meaningful, deep and maintained response over 48 weeks Member news
14 Mar 2023 Oxurion provides update on recruitment for KALAHARI Phase 2, Part B trial of novel PKal inhibitor THR-149 in diabetic macular edema and announces Board changes Member news
More info? Ellen Telleir Communications Project Manager linkedin.com/in/ellentelleir/ ellen.telleir@biovia.be Contact us
